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Abstract
Background: With ambitious new UNAIDS targets to end AIDS by 2030, and new WHO treatment guidelines, there
is increased interest in the best way to scale-up ART coverage. We investigate the cost-effectiveness of various ART
scale-up options in Uganda.
Methods: Individual-based HIV/ART model of Uganda, calibrated using history matching. 22 ART scale-up strategies
were simulated from 2016 to 2030, comprising different combinations of six single interventions (1. increased HIV
testing rates, 2. no CD4 threshold for ART initiation, 3. improved ART retention, 4. increased ART restart rates, 5.
improved linkage to care, 6. improved pre-ART care). The incremental net monetary benefit (NMB) of each
intervention was calculated, for a wide range of different willingness/ability to pay (WTP) per DALY averted (health-
service perspective, 3% discount rate).
Results: For all WTP thresholds above $210, interventions including removing the CD4 threshold were likely to be
most cost-effective. At a WTP of $715 (1 × per-capita-GDP) interventions to improve linkage to and retention/re-
enrolment in HIV care were highly likely to be more cost-effective than interventions to increase rates of HIV
testing. At higher WTP (> ~ $1690), the most cost-effective option was ‘Universal Test, Treat, and Keep’ (UTTK),
which combines interventions 1–5 detailed above.
Conclusions: Our results support new WHO guidelines to remove the CD4 threshold for ART initiation in Uganda.
With additional resources, this could be supplemented with interventions aimed at improving linkage to and/or
retention in HIV care. To achieve the greatest reductions in HIV incidence, a UTTK policy should be implemented.
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Background
Approximately 1.5 million people died from HIV-related
illnesses in 2013, with sub-Saharan Africa accounting for
74% of deaths [1]. In the same year, 2.1 million people
were newly infected with HIV. Uganda had an adult
(15–49 years) HIV prevalence of 7.3% at the time of the
last prevalence survey in 2011, and it is estimated that
around 95,000 people were newly infected with the virus
in 2014 [2]. Anti-retroviral therapy (ART) coverage of all
HIV infected adults in Uganda was estimated to be
around 51% in 2014 [2].
UNAIDS recently announced ambitious new targets to
‘end AIDS by 2030’ – fewer than 200,000 new infections
among adults- with goals for 2020 of 90% of HIV posi-
tive people knowing their status, 90% ART coverage
among people who know their status, and 90% viral sup-
pression among people on ART [3]. The Ugandan
Ministry of Health targets are equally ambitious: their
2015/2016–2019/2020 National HIV and AIDS Strategic
Plan sets the goal of a 70% reduction in adult HIV inci-
dence by 2020 [4]. To achieve these goals, ART coverage
in Uganda will need to increase dramatically over the
next few years.
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ART and HIV care coverage in Uganda and other sub-
Saharan African countries could be increased in a range
of different ways [5–20], and it is not clear what is the
most cost-effective option. Uganda’s Strategic Plan lists a
number of objectives, including scaling-up coverage of
HIV testing, increasing linkage to care, and strengthen-
ing community level follow-up and treatment support
mechanisms for people in pre-ART and ART care [4].
Other potential options include adopting the latest
WHO guidelines, which recommend ART for all people
diagnosed as HIV positive [21], or adopting a ‘universal
test and treat’ strategy, combining universal ART eligibil-
ity for all HIV positive people with a comprehensive
programme of HIV testing [20].
In this study, we use mathematical modelling to esti-
mate the costs and effects of different ART scale-up op-
tions, and identify the most cost-effective options at
different willingness to pay (WTP) per disability-
adjusted life-year (DALY) averted thresholds.
Methods
Model description
A dynamic, agent-based model of HIV transmission and
ART scale-up was developed in NetLogo [22]. The
model simulates the formation and dissolution of sexual
partnerships, HIV transmission, pre-ART and ART, and
drug resistance. The model was designed to accurately
represent major routes into and through HIV care in
Uganda (summarised in Fig. 1). A full description is
given in Additional file 1.
Data sources and analysis
The model was fitted to data on demography and trends
in HIV prevalence over time in Uganda; data on sexual
behaviour from a rural general population cohort in
South-West Uganda [23, 24]; and routinely collected na-
tional data on the proportion of HIV+ adults who were on
ART, the proportion of ART initiators who started with a
CD4 count of <250 cells/μl, in 2005, 2007, 2009, 2011, and
2013, and 12-month retention on ART in 2014 [25, 26].
The square root of CD4 count was assumed to decline
linearly over time [27]. To capture the effects of the intro-
duction of Option B+ in Uganda, the model was fitted to
data on the proportion of ART initiators who were
women in 2010, and the increase in the proportion who
were women between 2010 and 2014 [25, 28].
Ethical approval for the sexual behaviour data collec-
tion and analysis was granted by the Uganda Viral
Research Institute Ethics committee and the Ugandan
National Council for Science and Technology. All other
data used were obtained from publicly available sources.
In total, 51 outputs were fitted, and 96 inputs were
allowed to vary during the fitting process. For full details
see Additional file 1, which includes a table of input and
output ranges; Additional file 2, which explains the ra-
tionale for the choices of input and output ranges; and
Andrianakis et al. (2016) [29].
Fitting method
The model was fitted to the empirical data using history
matching with model emulation, which allowed uncer-
tainties in model inputs and outputs to be fully repre-
sented, and allowed realistic estimates of uncertainty in
model results to be obtained. History matching is a pro-
cedure that identifies and iteratively rejects parts of the
model’s input space (input combinations) that are un-
likely to produce model outputs within the plausible
ranges [29, 30]. The model is first run at a range of dif-
ferent input parameter combinations, spanning the
range of the model’s input space. Emulators are then
trained using these model runs, and are used to predict
the value of model outputs at points between the model
runs. Areas of input space where the emulator predic-
tions are very far from the empirical data are then dis-
carded. This process is then repeated iteratively, with the
model input space shrinking each time. The process is
stopped when the input space is sufficiently small for an
adequate proportion of model runs to fit the model out-
puts. Further details are given in Additional file 2, and in
Andrianakis et al. (2016) [29]. Using this method, we
generated 100 model fits.
Baseline and interventions
Using the calibrated model, we explored the effects of
six different intervention components:
1. Increased HIV testing (testing rate doubled)
2. No CD4 threshold for ART initiation
3. Improved retention on ART (drop-out rates halved)
4. Improved ART restart rates (restart rates doubled)
5. Improved linkage to care (linkage probability doubled)
6. Improved pre-ART care (pre-ART drop-out rates
halved, rate of starting ART from pre-ART care
when eligible doubled, linkage probability doubled)
Full details are given in Additional file 1. Using these
six intervention components, a total of 21 intervention
scenarios were simulated:
1. Each single intervention component (six interventions).
2. All plausible combinations of two components
(13 interventions) (interventions combining
universal access to ART and improved pre-ART care
were considered implausible).
3. Two intensive, multi-component interventions:
universal test and treat (UTT; components 1,2,
and 5) and universal test, treat, and keep (UTTK;
components 1–5).
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The costs and effects of different intervention scenar-
ios were compared to a baseline scenario, where no in-
terventions were implemented. Interventions were
implemented at the start of 2016, and the model was
run until the end of 2030. Results were averaged over
2000 (stochastic) repetitions for each scenario and model
fit.
For the purposes of some analyses, it was beneficial to
have estimates of the costs and effects of all plausible
combinations of three or more intervention compo-
nents. Due to computing resource constraints, it was
not possible to explicitly simulate all 21 (including UTT
and UTTK) of these interventions. Instead, the costs
and benefits of three/four component interventions were
estimated by summing the effects of simulated interven-
tions. Full details are given in Additional file 2.
Costs and DALYs
A health-systems approach was used in calculating costs.
Twenty cost parameters were used in calculating the
costs of each scenario. Fifteen of the costs were common
to all interventions, and included 1st and 2nd line drug
costs; healthcare costs arising from HIV-related morbid-
ity while not in care, in pre-ART care, and on ART (by
CD4 count); programme costs for pre-ART and ART
programmes; and HIV and CD4 test costs. Five costs
Fig. 1 Summary of the simulated care pathway
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were directly related to the costs of implementing the in-
terventions, and included increased programme costs, de-
creased or increased costs of additional HIV tests, and
increased costs of positive HIV tests for interventions that
increased linkage to care. Plausible ranges for cost param-
eters were determined using published data sources.
Plausible ranges and sources for cost parameters are given
in Table 1, and full details are given in Additional file 2.
Four DALY parameters were used in estimating the
impact of interventions: a parameter which determined
the relationship between CD4 count and disability, a dis-
ability weight for people who had continuously been on
ART for more than six months, a parameter which de-
termined the reduction in morbidity while in pre-ART
care, and a parameter that determined the reduction in
morbidity during the first six months on ART. Plausible
ranges and sources for cost parameters are given in
Table 1, and full details are given in Additional file 2.
All costs and DALYs were discounted by 3% per year.
DALYs were not age-weighted. For each of the 100
model fits, 20 parameter sets were created, with different
cost and DALY parameter values. This gave a total of
2000 parameter sets. Cost and DALY parameter values
for the 2000 parameter sets were selected using Latin
hypercube sampling. For each intervention and param-
eter set, the additional costs of the intervention, and the
additional number of DALYs averted (in comparison to
the baseline scenario) were calculated. Full details are
given in Additional file 2.
The incremental net monetary benefit (NMB) of each
intervention for each parameter-set was calculated, for a
wide range of different willingness/ability to pay (WTP)
per DALY averted thresholds (the value ascribed to a
DALY) ($0–$2500), using the formula NMB = DALYs
averted x WTP – cost. The most cost-effective interven-
tion for each parameter-set at a WTP threshold was
considered to be the intervention with the highest NMB.
We present our results using both WHO thresholds
(results section ‘Cost-effectiveness (WHO thresholds)),
and using a net monetary benefit approach (results sec-
tion ‘Net monetary benefit’).
Sensitivity analysis
In the main analyses, all people aged 50+ years were re-
moved from the model, and neither their costs to the
health services nor DALYs averted were considered. In a
sensitivity analysis, we explored the effects of including
the costs and DALYs averted in people aged 50–69. Full
details are given in Additional file 2.
Results
Fit to data
The model fitted closely to the plausible ranges for all
outputs. Figure 2 shows the fit to data for 31 outputs,
including male and female HIV prevalence over time,
ART coverage (among all HIV positive people), and HIV
testing. Fits to the other 20 model outputs are shown in
Additional file 3. Histograms of key input parameter
values in the 100 model fits are shown in Fig. 3, and for
all input parameters in Additional file 4.
Impact of interventions
Impact on HIV incidence in 2030
Figure 4 shows the reduction in HIV incidence in 2030
in the intervention scenarios compared to baseline. The
reductions in incidence were: 5.2% (90% plausible range
of 2.9–7.8%) with increased HIV testing, 4.1% (0.97–
8.8%) with no CD4 threshold, 29% (23–35%) with im-
proved retention on ART, 18% (13–28%) with increased
ART restart rates, 10% (6.0–13%) with improved linkage
to care, 11% (6.8–14%) with improved pre-ART care,
19% (9.6–27%) with UTT, and 55% (43–67%) with
UTTK.
Cost-effectiveness (WHO thresholds)
The majority of interventions were highly cost-effective
(cost less than Uganda’s per capita GDP per DALY
averted) or cost-effective (cost between one and three
times Uganda’s per capita GDP per DALY averted) in
more than 75% of parameter sets (Fig. 5). The two ex-
ceptions were increased HIV testing, and a combination
of increased HIV testing and removing the CD4 thresh-
old for ART initiation, which were not cost-effective
(cost more than three times Uganda’s per capita GDP
per DALY averted) for the majority of parameter sets.
Plots of DALYs averted against intervention costs are
shown in Additional file 3.
Net monetary benefit
Figure 6a shows a cost-effectiveness acceptability
curve for all intervention options (including baseline),
at willingness to pay thresholds (WTP) of $0–2500
per DALY averted. With a WTP of $0, removing the
CD4 threshold is more cost-effective (has higher net
monetary benefit) than the baseline scenario in 38%
of parameter sets, indicating that it may be cost-
saving. At intermediate thresholds of around $400–
1500 (0.56–2.1 times per capita GDP), there is a large
degree of uncertainty concerning the most cost-
effective option. However, the model suggests that in-
terventions that include increased HIV testing are un-
likely to be among the most cost-effective options. At
higher thresholds of above $1690 (2.4 times per capita
GDP), UTTK is the most cost-effective option in 50–
82% of parameter sets.
Figure 6b shows the proportion of parameter-sets
where each individual intervention component is in-
cluded in the most cost-effective intervention option, for
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WTP of $0–$2500. This was generated using the esti-
mated costs and effects of both simulated interventions,
and interventions combining three or more intervention
components (see Additional file 2 for further details of
the combined interventions). Removing the CD4 thresh-
old is included in the most cost-effective intervention in
50–75% of parameter sets for all WTP thresholds >£210
per DALY averted. Increasing ART restart rates and im-
proving linkage to care are included in >50% of param-
eter sets at WTP > $400 and WTP > $570 respectively,
reaching 100% of parameter sets at WTP > $980 and
WTP > $1770. The proportion of parameter-sets where
the most cost-effective intervention includes improv-
ing ART retention increases gradually at WTP thresh-
olds of >$100, reaching >50% of parameter-sets at
$1010, and >75% at $1510. The proportion of
parameter-sets where improved pre-ART care is in-
cluded in the most cost-effective option never in-
creases above 23%. Finally, increased rates of HIV
testing is never part of the most cost-effective inter-
vention at WTP thresholds of below $650, and is part
of the most cost-effective option in a maximum of
30% of parameter sets at the maximum threshold we
considered of $2500.
Table 1 Plausible ranges and sources of cost and DALY parameters
Name Description Plausible range Source
1st_line_drug_cost Annual cost of 1st line antiretroviral drugs, per person 118–137 USD Uganda Ministry of Health (2013)
[31] and WHO (2015) [32]
2nd_line_drug_cost Annual cost of 2nd line antiretroviral drugs, per person 151–330 USD Uganda Ministry of Health (2013)
[31] and WHO (2015) [32]
preART_program_cost Annual pre-ART program costs, per person 79–316 USD Menzies et al. (2011) [33]
early_ART_program_cost Annual program costs of providing ART for 1st
six months, per person
112–449 USD Menzies et al. (2011) [33]
reduced_cost_established_ART Reduction in program costs after 6 continuous months
on an ART regimen
0.7–1 Menzies et al. (2011) [33]
HIV_test_cost Cost per HIV test 5.51–7.05 USD Nichols et al. (2014) [34] and
Mulogo et al. (2013) [35]
CD4_test_cost Cost per CD4 test 5.18–17.48 USD Kahn et al. (2011) [36] and
Lara et al. (2012) [37]
clinic_visit_cost Average cost per clinic visit (due to HIV-related morbidity) 2.49–9.94 USD Pitter et al. (2007) [38]
hospital_night_cost Average cost of a night’s stay in hospital 3.95–15.80 USD Pitter et al. (2007) [38]
nights_per_hospital_visit Average duration of an inpatient hospital stay, in nights 3–7 Pitter et al. (2007) [38]
hospital_nights_parameter Determines the relationship between CD4 count and
the rate of inpatient hospital stays per year for
HIV+ people not receiving ART or pre-ART care
(see Additional files 1 and 2 for details)
−147.9 - -79.4 Mermin et al. (2008) [39]
reduced_hospital_pre-ART_care Reduction in inpatient hospital visits for HIV+ people
receiving pre-ART care
0.48–0.98 Mermin et al. (2008) [39]
reduced_clinic_pre-ART_care Reduction in clinic visits for HIV+ people receiving
pre-ART care
0.73–0.995 Mermin et al. (2008) [39]
reduced_hospital_ART Increased reduction in inpatient hospital visits for
HIV+ people on ART compared to people receiving
pre-ART care
0.32–0.78 Mermin et al. (2008) [39]
clinic_hospital_visit_ratio Ratio of clinic visits to inpatient hospital stays 2–5 Mermin et al. (2004) [40]
additional_HIV_test_increased_cost Increased cost of HIV tests conducted as part of an
intervention (relative to baseline cost)
−0.5 - 0.5 Menzies et al. (2009) [41] and
Tumwesigye et al. (2010) [42]
improved_linkage_to_care_cost Increase in cost per positive HIV test associated with
interventions to improve linkage to care.
0–20 USD Expert knowledge
reduced_ART_drop_out_cost Increase in ART program costs per person per year to
improve retention
0–50 USD Chang et al. (2010) [43] and
Chang et al. (2013) [44]
increase_ART_restart_cost Cost of increasing ART restart rates per dropout per year 0–50 USD Chang et al. (2010) [43] and
Chang et al. (2013) [44]
reduced_preART_drop_out_cost Increase in pre-ART program costs per person per year
to improve pre-ART care
0–50 USD Chang et al. (2010) [43] and
Chang et al. (2013) [44]
Full details of the cost and DALY parameters used are given in Additional file 2
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Sensitivity analysis
Including the costs and DALYs averted in people aged
50–69 had little effect on the results of any of the ana-
lyses (see Additional file 3).
Discussion
Our model results suggest that the optimum interven-
tion varies with the WTP per DALY averted. At all
WTP > $210, removing the CD4 threshold for ART ini-
tiation is included as part of the most cost-effective
intervention for more than 50% of parameter-sets. In
addition, it is cost-saving for 38% of parameter sets.
Based on this, we recommend that the CD4 threshold
for ART initiation in Uganda is removed, in line with
WHO guidelines. At intermediate WTP thresholds of
around $715 (Uganda’s per capita GDP in 2014), there is
large amount of uncertainty in the optimum interven-
tion(s). Our results suggest, however, that interventions
aimed at improving linkage to and retention/re-enrolment
in HIV care are highly likely to be more cost-effective than
interventions to increase rates of HIV testing in the gen-
eral population. At these thresholds, universal access to
ART for all people diagnosed with HIV should be supple-
mented with additional interventions aimed at improving
linkage to and/or retention in HIV care. Finally, at high
WTP thresholds of above around 2.4 times Uganda’s per
capita GDP, we found that universal test, treat, and keep
(UTTK) was the most cost-effective option.
UNAIDS recently published ambitious new targets to
‘end the AIDS epidemic by 2030’ [3]. To achieve this, it
will be necessary to intensively scale-up HIV care pro-
grammes and ART provision throughout sub-Saharan
Africa. A ‘universal test and treat’ policy – combining
large-scale programmes of HIV testing with universal ac-
cess to ART – is frequently promoted as a way of greatly
reducing HIV incidence and mortality. We demonstrate
that improving retention on ART should also constitute
a key policy component in the drive to eliminate HIV.
For this reason, we advocate a ‘universal test, treat, and
keep’ policy.
A great strength of our work is the comprehensive in-
corporation of a large number of the potential sources of
uncertainty in our results, through allowing a large num-
ber of model inputs to vary during the model fitting,
and through fitting to realistic plausible ranges on a
large number of model outputs. This was made possible
through our use of an innovative fitting method: history
matching using model emulation. In addition to this, we
also incorporated uncertainty in costs and HIV disability
weights in our analysis of the model output. Our results
a)
d)
g)
b)
e)
h)
c)
f)
i)
Fig. 2 Model baseline fit to empirical data. Graphs a-f: Black dots show the empirical estimates, and the error bars show the plausible ranges for
the output values. Black lines show the median model output. Blue/green bands show 10% quantiles of model outputs, from the 100 model fits.
The full width of the band shows the range of the model output. Graphs g-i: Orange boxes show the empirical data and plausible ranges. Green
boxes show the model output. Model fits to the remaining 20 outcomes are show in Additional file 3
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a) b) c) d)
e) f) g) h)
i) j) k) l)
Fig. 3 Histograms of key input parameter values in the 100 model fits. a Baseline* rate of testing for HIV per month from 2012, in men who have
not been tested within the past 6 months. b Baseline* rate of testing for HIV per month from 2012, in women who have not been tested within
the past 6 months. c Increased rate of testing in HIV+ people (multiplicative). d Baseline* proportion of women linked to care following a positive
HIV test, from 2012. e Proportion of men linked to care following a positive HIV test, from 2012, relative to proportion of women. f Coverage of
B+ (following its adoption). g Baseline* rate of dropping out of ART in men, per month. h Baseline* rate of dropping out of ART in women, per
month. i Increased rate of dropping out of ART in the first 12 months following ART initiation. j Increased rate of dropping out of pre-ART care,
relative to the rate of dropping out of ART. k Baseline* rate of restarting ART in men, per month. l Baseline* rate of restarting ART in women, per
month. *Before adjustment for adherence/health seeking behaviour. Histograms for all model inputs are shown in Additional file 4
Fig. 4 Relative reduction in HIV incidence in 2030 in the intervention scenarios, compared to baseline. Boxes show the median and 25–75%
quartiles. Crosses show the 90% plausible range. White boxes show the results for the various single intervention components, UTT, and UTTK.
Shaded boxes show the results for combinations of two intervention components. Results for two-component interventions are shown twice,
once for each intervention component
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Fig. 5 Distribution of cost per DALY averted for each intervention. White boxes show the results for single intervention components, UTT, and
UTTK. Shaded boxes show the results for combinations of two intervention components. Boxes show the median and 25–75% quartiles. Crosses
show the 90% plausible range. Results for two-component interventions are shown twice, once for each intervention component. Red, yellow,
and green bands show areas where intervention are considered not cost-effective (cost >3 × Uganda’s per capita GDP per DALY averted,
>$1430), cost-effective (cost 1–3 × Uganda’s per capita GDP per DALY averted, $715–$1430), and highly cost-effective (cost <1 × Uganda’s per
capita GDP per DALY averted, <$715) respectively. In this figure, parameter sets are excluded from the results for an intervention if the number of
DALYS averted is less than zero. The maximum number of parameter sets excluded for any intervention is 134/2000 (6.7%)
a) b)
Fig. 6 Cost-effectiveness acceptability curves. a Lines show the proportion of parameter sets for which an intervention is the most cost-effective
option (highest net monetary benefit), for different willingness to pay per DALY averted thresholds. Interventions which are the most cost-
effective option in less than 5% of scenarios at all willingness to pay thresholds are combined into the single category ‘other’. b Lines show the
proportion of parameter sets where the most cost-effective intervention includes each individual intervention component, for different willingness
to pay per DALY averted thresholds. Combinations of three and four interventions were included in the analysis for Fig. 6b, but not for Fig. 6a
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demonstrate the critical importance of this process.
While we are very confident in our recommendations
for low and high WTP thresholds, there is far more un-
certainty in the optimum intervention at intermediate
WTP thresholds of around one times Uganda’s GDP. In-
adequate representation of the uncertainty that exists in
current conditions would have led to an underestimate
of the uncertainty in future predictions. This in turn
would have led to overconfident, and potentially dele-
terious, recommendations being made.
We chose to model the effects of the different inter-
ventions components – for instance a 50% reduction in
the rate at which people drop out of ART – rather than
the activities themselves – for instance the use of peer
health workers to encourage people to remain in care –
to increase the generalisability of the results. Whether
possible, both key resource costs (e.g. drugs and care for
HIV-related morbidity), and the costs of implementing
interventions, were informed by empirical studies from
Uganda. There were some gaps in the empirical cost
data available however, including in the additional costs
required to scale-up interventions. We therefore chose
wide acceptable ranges for intervention cost parameters.
This meant that the uncertainties in input parameter
values were accounted for in our analyses, as they were
projected forward into the uncertainty estimates we
show for our results, and the levels of confidence we
place in our conclusions.
Our results strongly suggest that an increase in the
rates of HIV testing in the general population in Uganda
is only likely to be a cost-effective option at high WTP
thresholds, and that it should not be prioritised above
interventions to improve linkage to, and retention in,
care. This reflects the fact that overall rates of HIV test-
ing in Uganda are already relatively high: approximately
50% of Ugandan adults were tested and received their
results in 2014 [2]. Interventions to increase rates of
HIV testing may be more cost-effective in other popula-
tions, both in countries with lower general population
rates of HIV testing, and in sub-populations in Uganda
with lower testing rates and/or higher HIV incidences.
A limitation of our work is that we were unable to
simulate all possible combinations of individual inter-
vention components, due to computing resource con-
straints. Comparing the costs and DALYs averted of
single vs double interventions suggested there was little
interaction between most pairs of intervention compo-
nents (Additional file 3). This allowed us to combine in-
terventions additively for the purposes of determining if
an individual intervention component is included in the
most cost-effective intervention for each parameter-set
and WTP. This approach may underestimate uncertainty
in the differences in costs and effects between different
interventions however, and so was not used for the main
analysis. The single three-component intervention we
simulated (UTT) was highly unlikely to be more cost-
effective than UTTK at any WTP. It is nevertheless pos-
sible that three or four component interventions that we
did not simulate may be the most cost-effective option
at some WTP thresholds, particularly at WTP thresh-
olds around the range where UTTK first becomes the
optimum intervention.
Conclusions
We recommend that the CD4 threshold for ART initi-
ation in Uganda is removed, in line with current WHO
guidelines. At higher WTP thresholds, and if sufficient
resources are available, this should be supplemented
with interventions aimed at improving linkage to and/or
retention in HIV care. Finally, to achieve the greatest re-
ductions in HIV incidence, a universal test, treat and
keep policy should be implemented, combining in-
creased rates of HIV testing, universal access to ART for
all people diagnosed with ART, and measures to improve
retention in care. More generally, in Uganda, interven-
tions to improve retention in and movement through
the HIV care pathway should be prioritised over case
finding interventions in the general population.
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